Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-3095 in Healthy Participants
NCT07686484Phase 1Active, not recruiting
- Sponsor
- Atridia Pty Ltd
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-3095 in chronic spontaneous urticaria (CSU) (3 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Incidence and Severity of Treatment Emergent Adverse Events at Day 8. Started Jul 2026; status: active, not recruiting.
02
Drugs
HRS-3095
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07686484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686484.